Achievement of cure following allogeneic HSCT with Flu-Bu regimen in a patient with severe mycosis fungoides and Sezary Syndrome
Article Sidebar
Main Article Content
Article Details
Copyright (c) 2019 Yeral M.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015; 26: 2490-2495. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26416896
Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014; 49: 1360-1365. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25068422
Şanlı H, Akay BN, Saral S, Okçu Heper A, Topçuoğlu P. Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation. Turk J Haematol. 2017; 34: 194-195. https://www.ncbi.nlm.nih.gov/pubmed/28008858
Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, et al. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). Int J Hematol. 2017; 106: 426-430. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28466385
Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, et al. Allogeneic hematopoietic cell transplantatıon for mycosis fungoides and sezary syndrome. Bone Marrow Transplant. 2014; 49: 1360–1365. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25068422
Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, et al. Treatment of advanced mycosis fungoides by allogeneic stemcell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant. 2003; 31: 663- 666. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12692606
Herbert KE1, Spencer A, Grigg A, Ryan G, McCormack C, et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34: 521-525. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15286686
Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28: 4492–4499. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20697072
Yang J, Cai Y, Jiang JL, Wan LP, Yan SK, et al. Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors. Blood Cancer J. 2015; e332.